The conditional promise of dual-epitope HER2 antibody-drug conjugates in breast cancerOA
In the landscape of neoadjuvant therapy for breast cancer,achieving a pathologic complete response(pCR)to improve long-term survival remains the paramount clinical objective1.Although traditional dual human epidermal growth factor receptor 2(HER2)-targeted therapies combined with chemotherapy have improved pCR rates in HER2-positive breast cancer2,their associated systemic toxicities and current efficacy plateaus have compelled researchers to seek more precise alternative strategies.
Ruoqing Wang;Shuhao Jiang;Qun Zhang;Junjie Li
Department of Breast Surgery,Key Laboratory of Breast Cancer in Shanghai,Fudan University Shanghai Cancer Center,Shanghai 200032,China Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,ChinaDepartment of Breast Surgery,Key Laboratory of Breast Cancer in Shanghai,Fudan University Shanghai Cancer Center,Shanghai 200032,China Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,ChinaDepartment of Breast Surgery,Key Laboratory of Breast Cancer in Shanghai,Fudan University Shanghai Cancer Center,Shanghai 200032,China Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,ChinaDepartment of Breast Surgery,Key Laboratory of Breast Cancer in Shanghai,Fudan University Shanghai Cancer Center,Shanghai 200032,China Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China
医药卫生
breast cancerHer targeted therapiesdual epitope Her antibody drug conjugateslong term survivalpathologic complete response pcrneoadjuvant therapypathologic complete responsesystemic toxicities
《Cancer Biology & Medicine》 2026 (9)
P.1205-1212,8
supported by the National Natural Science Foundation of China(Grant No.82172576).
评论